The PHARM Connect Congress - Kongres PHARM Connect- Najlepsze Wydarzenie Farmaceutyczne i Biotechnologiczne w Europie Środkowo- Wschodniej
linkedin
facebook
Twitter
Youtube
 
Już po 7 raz w dniach 22-23 lutego 2017  
*****Corinthia Hotel Budapeszt, Węgry Zaloguj się do harmonogramu spotkań demo CZE ENG HUN POL ROU
  1. PHARM Connect
  2. Program
  3. Nagrody
  4. Video
  5. Wiadomości
vr

PHARM Connect

Kongres PHARM Connect

Kongres PHARM Connect jest największym i najważniejszym farmaceutycznym i biotechnologicznym szczytem biznesowym w Europie Środkowej i Wschodniej oraz w regionie WNP, który corocznie odbywa się w lutym w Budapeszcie.

Od rozpoczęcia organizacji pierwszej edycji w 2011 roku, liczba uczestników osiągnęła ponad 500 z ponad 20 krajów w regionie i poza nim. W ciągu dwóch dni Kongresu wiodący dostawcy usług z sektora farmaceutycznego i biotechnologicznego - obejmujący szeroki zakres profili od produkcji API i zamówień kontraktowych do przetwórstwa, biofarmaceutycznych rozwiązań, biofarmaceutyków, systemów dostarczania leków, zachowania czystości miejsca pracy, sprzętu laboratoryjnego, monitoringu i systemu kontroli, kontroli jakości, pakowania i etykietowania, automatyki, inżynierii i strategii w utrzymaniu ruchu, logistyki, magazynowania, dystrybucji i zimnego łańcucha dostaw do magazynowania i wielu innych – uczestnicy mają unikalną okazję spotkać najważniejszych brażowych decydentów z celowych spółek.

 

Elitaryzm

Warunkiem wzięcia udziału w Kongresie jest otrzymanie zaproszenia, które gwarantuje najwyższy poziom delegacji. Każdy dostawca usług biorący udział w PHARM Connect jest wybierany w oparciu o potrzeby i zainteresowania określone z wyprzedzeniem przez uczestników

 

Najbardziej aktualne dane rynkowe

W celu zapewnienia wysokiej jakości programu konferencji, ściśle współpracujemy z wiodącymi lokalnymi i regionalnymi stowarzyszeniami, europejskimi i międzynarodowymi partnerami medialnymi oraz z naszym Komitetem Doradczym Programu, którego członkowie to znani i cenieni eksperci farmaceutyczni i biofarmaceutyczni z wiodących międzynarodowych firm. Program konferencji obejmuje najbardziej aktualne dane rynku w zakresie: badań i rozwoju, produkcji, inżynierii, zarzania łańcuchem dostaw i tematy związane z zarządzaniem jakością.

Wcześniej zaplanowane spotkania biznesowe

Przez dwa dni podczas trwania zaaranżowanych z wyprzedzeniem spotkań biznesowych one-to-one, oraz innych działań networkingowych, wystawcy mają okazję spotkać się z osobami decyzyjnymi  zwiększając tym samym wydajność firmy, tworząc wyjątkową okazję do rozwijania znaczących i wartościowych relacji biznesowych.

Kongres oferuję także niepowtarzalną okazję do wzięcia udziału w specjalnie zorganizowanych wizytacjach do zakładów produkcyjnych w celu zapoznania się z głównymi producentami farmaceutycznymi w regionie- harmonogram ustalany jest przed rozpoczęciem Kongresu i jest dostępny w Meeting Scheduler.

Pięciogwiazdowa lokalizacja

Najlepszy biznes osiąga się zawsze w doskonałym i sprzyjającym otoczeniu, dlatego nasz Kongres organizujemy w luksusowym pięciogwiazdkowym Corinthia Grand Hotel w centrum Budapesztu.

Wiadomości

03/25/2016

PHARM Connect 2016 - Post Event Press Release

PHARM Connect 2016 - Post Event Press Release New collaborations born and challenges addressed at the leading pharmaceutical business summit

Read more

03/17/2016

Interview with Videojet

Interview with Videojet Videojet won the 2nd CEE Pharmaceutical Manufacturing Excellence Award at PHARM Connect - the market leading pharmaceutical and biotechnology manufacturing business summit for CEE. 

Read more

Subskrybcja newsletter'a

Będziemy Państwa informować na bierząco w sprawach dotyczących Konferencji oraz programu. 

Jeśli chcą Państwo otrzymywać więcej informacji dotyczących Konferencji PHARM Connect, prosimy o zasubskrybowanie naszego newsletter'a here przeszłając nam swój adres e-mailowy wpisując w temacie wiadomości "subskrybcja".

Dziękujemy za zainteresowanie.

 

Jeśli nie chcą Państwo dłużej otrzymywać od nas newsletter'a, prosimy o przesłanie "usunięcie subskrybcji" w temacie wiadomości swojego e-maila. 

video

PHARM Connect Congress 2016 LIVE

TEG The Events Group

video

PHARM Connect 2015 LIVE

TEG The Events Group

video

PHARM Connect 2015

One-to-One interview with Terry Siggins, GE IP

Nagrody

Videojet Technologies received the 2nd Central Eastern European Pharmaceutical Manufacturing Excellence Award in 2016

 

TEG with the support of the Hungarian Pharmaceutical Manufacturers Association (MAGYOSZ) handed out the 2nd Central Eastern European Pharmaceutical Manufacturing Excellence Award in 2016 to honour, recognise and promote outstanding manufacturing excellence solutions in the rapidly growing region of CEE. The award was handed out at the award ceremony at the PHARM Connect Congress 2016 in Budapest.

The 2nd Central Eastern European Pharmaceutical Manufacturing Excellence Award ceremony together with the cocktail reception was opened by Dr. Lajos Hegedüs former Managing Director of Teva Pharmaceuticals Hungary and now the Chairman of the Production Commission at MAGYOSZ who announced the winner and handed out the award to Videojet Technologies, emphasising that these tried method will encourage professionals to constantly raise standards and come up with outstanding manufacturing excellence solutions, to further contribute to the development of the rapidly growing CEE region.

In the picture: Dr. Lajos Hegedűs, Chairman Production Commission, MAGYOSZ


The jury selected the joint winner for the following reasons:

  • Videojet winner designed a Thermal inject printer for integration into complex track and trace lines.
  • In cooperation with a solution provider company they conducted comprehensive trials to confirm the product’s    suitability in terms of integration, performance and control.
  • Several new innovative features had been built into the product. To meet certain physical constrains the printer is 60% smaller than comparable legacy print controllers. It offers a range of possibilities for secure integration. It offers innovative, new possibilities to add surplus print-heads. The product fitted with a display for presenting machine diagnostics, but with no ability to input data or to access printer control to avoid operator interference or errors.
  • Due to the built-in productivity improvements the new printer reduces ink consumption, reduce line stops and changeovers, reduce operator error and improve operational security.

 

In the picture: Chris Schneider, Global Product Manager Pharma and Heidi Vanheerswynghels, Sales Manager EMEA – Healthcare at Videojet Technologies Inc.

 


SPECIAL THANKS to the 2016 jury members who evaluated the applications by their level of level of cost-effectiveness, quality, service and innovation


 

Dr. Lajos Hegedűs

former General Manager 

TEVA

Chairman Production Commission  

MAGYOSZ

 

István Király

Managing Director

GSK Biologicals


Endre Kollár

Associate Vice President, Director of Germany-Hungary-India-Italy Production Group

Sanofi

Dr. Erik Bogsch    


Head of Biotechnology R&D Division

 

Gedeon Richter

 

If you think your solution is cutting-edge and should be recognised by the industry, apply now for the

3rd CEE Pharmaceutical Manufacturing Excellence Award until the 16th of January 2017 

and put your business in the spotlight!


For further details regarding the application for the 3rd CEE Pharmaceutical Manufacturing Excellence Award please click here or contact 

Katy Säurich, Head of Production & Operations at TEG

Tel:        + 36 1 219-5725 
Email:    KatyS@tegevents.eu

Program

Kongres PHARM Connect 2017 ma na celu przedstawienie ogólnych inormacji na temat rynku w Europie Środkowo-Wchodniej i najważniejszych trendów oraz ich wpływie na branżę produkcji farmaceutycznej i biotechnologii.

W celu zapoznania się z możliwościami prowadzenia prezentacji, prosimy o kontakt z Katy Säurich, Kierownikiem ds. operacyjych i produkcji TEG lub pod nr tel: + 36 1 219-5725.

 

PHARM Connect Congress programme 2017


Keynote Presentation: TERROSA – First Biosimilar Approval for Gedeon Richter   

Dr. Erik Bogsch, Head of Biotechnology R&D, Gedeon Richter Dr. Ildikó Aradi, Head of Clinical Development of Biologics, Gedeon Richter Dr. Katalin Fogassy, TERROSA Project Manager, Gedeon Richter
  • Key development steps for biosimilars
  • Technology platforms applied
  • Medical device aspects
  • Clinical development programme challenges of biosimilars
  • A complex IP landscape
  • Market access challenges

Dr. Erik Bogsch, Head of Biotechnology R&D, Gedeon Richter 

Dr. Ildikó Aradi, Head of Clinical Development of Biologics, Gedeon Richter

Dr. Katalin Fogassy, TERROSA Project Manager, Gedeon Richter


 

Keynote Presentation: EU’s Falsified Medicines Directive (FMD): How to prepare now for the 2019 deadline?

Neil Lawrence, Global Serialisation Champion, Global Manufacturing and Supply, GlaxoSmithKline
  • Preparing for compliance: How to protect the market?
  • Global look at Big Pharma business-critical practicalities of serialisation
  • GSK best practice case study and lessons learnt 

Neil Lawrence, Global Serialisation Champion, Global Manufacturing and Supply, GlaxoSmithKline

 

Case Study Presentation: New Equipment and Equipment Substitutes – Best Practices of Integration and Process Validation

Dr. János Dombovári, Director Operational Excellence Pharma Division, TEVA Pharmaceuticals Works
  • Considerations during tablet press substitution: how to integrate the new machine into the existing production system and how to validate operation
  • How to handle differences and analogies
  • Incorporation of technical improvements into the production process

Dr. János Dombovári, Director Operational Excellence Pharma Division, TEVA Pharmaceuticals Works

 

 

Presentation: Regulatory and quality management system changes in Russian Pharma market: Recent developments and future perspective  

Ekaterina Tvorogova, Regulatory Affairs Manager, Egis Pharmaceuticals, Representation in Russia
  • The impact of main regulatory requirements on drugs turnover
           - Local clinical trials,Russian GMP inspections,
           - State quality control system,
           - Price regulation.  
  • Eurasian Union pharmaceutical market. What exactly was introduced and what are the expectations?

Ekaterina Tvorogova, Regulatory Affairs Manager, Egis Pharmaceuticals, Representation in Russia

 

Case Study Presentation: Challenges in meeting Good practices for data management and integrity in regulated GMP environments guidance

Dr. Piotr Lipinski, Quality Systems Manager/QP, Novartis Technical Operations - Platform Solids Europe, Lek / Sandoz
  • General requirements related to data integrity
  • Main FDA and EU inspections observations in scope of data management and integrity
  • Data management and Integrity program for pharmaceutical company

Dr. Piotr Lipinski, Quality Systems Manager/QP, Novartis Technical Operations - Platform Solids Europe, Lek / Novartis

 

Presentation: Concepts to improve the productivity of drug innovation 

Professor Péter Mátyus, Director of the Drug Discovery and Safety Centre and CEO of the Bionics Innovation Center, Semmelweis University Budapest
  • Trends in performance of drug innovation, an overview
  • Limitations of productivity
  • Some principles for (more) effective preclinical research
  • The possible contributions of University to drug discovery
  • Case studies

Professor Péter Mátyus, Director of the Drug Discovery and Safety Centre and CEO of the Bionics Innovation Center, Semmelweis University Budapest

 

Presentation: „Spread the Word”   

Dr. Lívia Ilku, Director, Hungarian Pharmaceutical Manufacturers Association (MAGYOSZ) Erzsébet Ódor, Country Security Partner, SANOFI
  • How are the fake drugs distributed?
  • Who buys on the internet?
  • How to inform the customers about the risk?
  • Program for generation Z
  • What is their reflection?

Dr. Lívia Ilku, Director, Hungarian Pharmaceutical Manufacturers Association (MAGYOSZ) 

Erzsébet Ódor, Country Security Partner, SANOFI & Head of the Hungarian Pharmaceutical Manufacturers Association (MAGYOSZ) Environment Subcommittee

 

Case Study Presentation: Industry 4.0 and Single Use Technology in BioPharma

Dirk Tillich, European Sales Director, Finesse Solutions
  • The 4th Industrial Revolution
  • Improving Competitiveness 
  • Impact for BioPharma
  • Continuous Manufacturing
  • Examples of implemented Smart Factories

Dirk Tillich, VP Global Sales, Core Business, Finesse Solutions

 

Case Study Presentation: Discover Pall’s full mAb Purification Platform 

Adriane Raninger, Bio-Purification Process Specialist CEE, Pall Life Sciences

The presentation illustrates recent evolutions in Bioprocessing and describes in detail all potential opportunities for a process platform run in continuous mode. The content rounds up with an overview of selected Pall products and gives useful application details in Downstream Processing.  

Adriane Raninger, Bio-Purification Process Specialist CEE, Pall Life Sciences

 

Case Study Presentation: Efficiency increase for single-use cell removal (Midstream) using filter aid and continuous process design

Ralph Daumke, Market Manager Biologics, FILTROX
  • Increasing cell removal efficiency
  • Continuous process
  • Cost effective process

Ralph Daumke, Market Manager Biologics, FILTROX  

 

  

Panel Discussion: EU’s Falsified Medicines Directive (FMD): How to protect the market?

 

Grzegorz Brzoskowski, Security Director CEE / Baltic, SANOFI

 

Réka Balogh, Leader of the Safety Feature Committee of the Hungarian Pharmaceutical Manufacturers Association (MAGYOSZ) & Serialization Project Coordinator, Quality Assurance Expert, TQM, Gedeon Richter Neil Lawrence, Global serialization Champion, Global Manufacturing and Supply, GlaxoSmithKline

Grzegorz Brzoskowski,

Security Director CEE / Baltic,

SANOFI

 

 

 

 

 

Réka Balogh,

Serialization Project Coordinator,

QA Expert, TQM, 

Gedeon Richter

& Leader of the Hungarian

Pharmaceutical

Manufacturers Association

(MAGYOSZ) Safety Feature Committee


 

Neil Lawrence,

Global serialization Champion,

Global Manufacturing and Supply,

GlaxoSmithKline 

 

 

 

 


 

 

 

Panel Discussion: Regulatory and quality management system changes in Russian & Ukrainian Pharma market

Introductory speech by Dr. Sergii Sur, Regulatory Affairs Director, Arterium Corporation

Dr. Sergii Sur, Regulatory Affairs Director, Arterium Corporation

Dr. Sergii Sur, Regulatory Affairs Director, Arterium Corporation

Ekaterina Tvorogova, Drug Regulatory Affairs Manager, EGIS Pharmaceuticals, Representation in Russia

Dr. Herta Pálfi Goóts,

 Director, Regulatory Affairs, 

Gedeon Richter &

Head of the Hungarian

Pharmaceutical Manufacturers

Association (MAGYOSZ)

 Regulatory Affairs Committee

Dr. Sergii Sur,

Regulatory Affairs Director,

Arterium Corporation

 

 


 

 

Ekaterina Tvorogova,

Drug Regulatory Affairs Manager,

EGIS Pharmaceuticals,

 Representation in Russia

 

 

 

 

 

 

Project Presentations by the Award Winners of the 3rd CEE Pharmaceutical Manufacturing Excellence Award

The award has been established to honour, recognise and promote outstanding manufacturing excellence solutions in the rapidly growing region of CEE. Manufacturers as well as solution providers are welcome to apply with their most innovative projects and methods implemented in the region. The winners will have the opportunity to present their projects at PHARM Connect 2017.


Applications should be submitted by 16th of January 2017 and will be assessed by our highly renowned independent regional academic jury.

Due to the overwhelming interest from the market we have decided to extend the

deadline to the 31st January 2017!!!


Further information click here

 

 

Additional Networking Activities

 Site visit to the GlaxoSmithKline Biologicals plant 

The congress provides the opportunity to visit GlaxoSmithKline Biologicals in Gödöllő limited for 50 delegates only and available on a first come first serve complimentary basis on February 21st at 1:00 p.m.

GlaxoSmithKline Biologicals Kft. is located in Gödöllő and is part of the GlaxoSmithKline Vaccines business branch. At the Gödöllő site GSK is producing, testing and releasing Tetanus and Diphtheria bulk antigens for shipment to other GSK Vaccines sites. About 220 people are involved in the manufacturing of antigens used in vaccines such as Synflorix™, Menitorix™, Hiberix™, and MenHibrix™. The Gödöllő site contributes to the 12% of the annual turn-over of GSK Vaccines.

The visit of the site will provide an opportunity to get more information about the activities of the Gödöllő site, the vaccine manufacturing process and the manufacturing facility of the biotechnology site. The site visit will start with an introduction of the GSK Vaccines business division and the Gödöllő site, including a short movie about the activities which is followed by a site tour including a visit to the manufacturing facility.

Delegates can select among the following three focus groups: 

  • Group A: production corridor, Biochemistry lab and warehouse
  • Group B: warehouse, production corridor, Microbiology lab
  • Group C: Microbiology lab, warehouse and production corridor

As for the outfit, jeans and comfortable shoes are required. Helmet is needed in warehouse, gowning (coat) in Biochemistry lab, gowning (coat) and shoe cover are needed in the Micobiology lab and will be provided before the visit.

Transfer: The bus will leave in front of the Corinthia Grand Hotel Royal on February 21st at 12:00 p.m. and will return after the visit at approximately 5:00 p.m.

 


Additional Networking Activities – Site visit to the Research Centre for Natural Sciences at the Hungarian Academy of Science (MTA TTK)

 Research Centre for Natural Sciences at the Hungarian Academy of Science (MTA TTK) 

The congress provides the opportunity to visit the Research Centre for Natural Sciences at the Hungarian Academy of Science (MTA TTK) in Budapest limited for 60 delegates only and available on a first come first serve complimentary basis on February 23rd a5:00 p.m. The MTA Research Centre for Natural Sciences carries out multidisciplinary research in natural sciences.  Priorities are given to the following disciplines:

-          Organic chemistry

-          Materials- and environmental chemistry

-          Molecular and cellular life sciences

-          Cognitive neuroscience and psychology

 

The visit will start with a short introductory presentation about the MTA TTK. Afterwards the delegates will have the opportunity choose a tour among the four research institutes:

 

Organic chemistry

Developing novel types of reaction, the synthesis of new ring frames and compounds in the field of organic small- and supramolecular molecules, determination of chemical structure and interpretation of experimental processes by instrumental techniques and theoretical calculations. 

 

Materials- and environmental chemistry

Research of discovery and experimental development in some key areas of materials- and environmental science, with special emphasis on chemical aspects thereof. Exploratory research in the field of nanoscale functional materials and application of the results in integrated nano/micro systems.

 

Enzymology

Researchers at the Institute of Enzymology investigate the structure of proteins and how they function – at the level of molecules through to complex organisms. They make use of the latest biochemical, imaging and genetic engineering methods to reveal the structure of proteins, their properties and the biological functions enzymes perform in the human body. Further important areas of research are signal processing and transmission, the regulation of protein breakdown and how cancer evolves. The researchers also want to find out what the actual protein composition of the cell looks like and how complete biological systems function. Target based drug development.

 

Cognitive neuroscience and psychology

Research of discovery and applications in experimental psychology, human-, developmental and comparative psychophysiology, social development psychology, social psychology and cultural psychology. 

 

Transfer: The bus will leave in front of the CORINTHIA Grand Hotel Royal on February 23rd at 4:00 p.m. and will return after the visit at approximately 8:00 p.m.

 

W celu zapoznania się z możliwościami prowadzenia prezentacji, prosimy o kontakt z Katy Säurich, Kierownikiem ds. operacyjych i produkcji TEG lub pod nr tel: + 36 1 219-5725.

vr
Sponsorzy
vr
Pall Life Sciences
Finesse Solutions
FILOTROX
Bird & Bird

Exclusive Legal Partner

GSK Vaccines

Exclusive Excursion Partner

MTA TTK

Exclusive Excursion Partner

View_further_vendors

vr
Przykładowa lista sponsorów
vr

View_further_vendors

vr
vr

View more

vr
Partnerzy medialni
vr
Exclusive Hungarian Media Partner
MarketingPirula- PirulaTrend

View more

vr

Kongres PHARM Connect- Najlepsze Wydarzenie Farmaceutyczne i Biotechnologiczne w Europie Środkowo- Wschodniej

vr

map

vr
| | Kontakt | Zarezerwuj teraz
TheEventsGroup © 2012 | Polityka prywatności |
Design: Nortyx Program: Nortyx Web and Recording studio, Stage technic